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Abstract: Few studies have examined the association of a wide range of metabolites with total and
subtypes of coffee consumption. The aim of this study was to investigate associations of plasma
metabolites with total, caffeinated, and decaffeinated coffee consumption. We also assessed the ability
of metabolites to discriminate between coffee consumption categories. This is a cross-sectional analysis
of 1664 participants from the PREDIMED study. Metabolites were semiquantitatively profiled using
a multiplatform approach. Consumption of total coffee, caffeinated coffee and decaffeinated coffee
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was assessed by using a validated food frequency questionnaire. We assessed associations between
387 metabolite levels with total, caffeinated, or decaffeinated coffee consumption (≥50 mL coffee/day)
using elastic net regression analysis. Ten-fold cross-validation analyses were used to estimate the
discriminative accuracy of metabolites for total and subtypes of coffee. We identified different
sets of metabolites associated with total coffee, caffeinated and decaffeinated coffee consumption.
These metabolites consisted of lipid species (e.g., sphingomyelin, phosphatidylethanolamine,
and phosphatidylcholine) or were derived from glycolysis (alpha-glycerophosphate) and polyphenol
metabolism (hippurate). Other metabolites included caffeine, 5-acetylamino-6-amino-3-methyluracil,
cotinine, kynurenic acid, glycocholate, lactate, and allantoin. The area under the curve (AUC) was
0.60 (95% CI 0.56–0.64), 0.78 (95% CI 0.75–0.81) and 0.52 (95% CI 0.49–0.55), in the multimetabolite
model, for total, caffeinated, and decaffeinated coffee consumption, respectively. Our comprehensive
metabolic analysis did not result in a new, reliable potential set of metabolites for coffee consumption.
Keywords: coffee; caffeine; plasma; metabolomics; PREDIMED
1. Introduction
Coffee, a widely consumed beverage worldwide [1], has been associated with both beneficial and
detrimental effects on health-related outcomes, although harmful associations have been shown to be
largely nullified by adequate adjustment for smoking [2]. The most commonly consumed types of
coffee, caffeinated and decaffeinated, have consistently been associated with a lower risk of type 2
diabetes (T2D) [3]. However, these findings are based on self-reported dietary assessment methods
that might be subject to some degree of misclassification or measurement error [4].
Metabolomics has the potential to advance nutritional epidemiology by objectively measuring
metabolic products of foods, and might therefore better accurately reflect food exposure [5].
A comprehensive metabolite profiling may also provide a deeper understanding of metabolic response
to foods providing new functional insight to their role in health. Particularly, coffee contains a variety
of compounds, many of which may impact metabolic pathways related to disease development
or prevention.
In this regard, coffee consumption has been found to be positively associated with two classes
of sphingomyelins and negatively associated with long- and medium-chain acylcarnitines in plasma
among 284 men of the KORA study population [6]. In a prospective study of 1610 EPIC-Potsdam
participants, coffee consumption was inversely associated with one diacylphosphatidylcholine in both
sexes and phenylalanine in men, whereas in women, coffee consumption was positively associated
with three acyl-alkyl-phosphatidylcholine species [7]. Other metabolites related to coffee exposure
include hydroxycinnamate derivatives, phenolic acid derivatives and dimethoxycinnamic acids [8–10].
Recently, a 3-stage coffee trial found 115 serum metabolites significantly associated with coffee
consumption among 47 participants [11]. Five metabolic pathways were significantly enriched: (a)
xanthine, (b) benzoate, (c) steroid, (d) fatty acid (acyl choline), and (e) endocannabinoid [11]. The same
research team extended this work to analysis of the lipidomic changes in response to coffee consumption
and found that coffee may induce alterations in glycerophospholipid metabolism [12]. However,
to date, limited or no metabolomic-analysis has been conducted using combinations of different
metabolomic platforms to cover a wide range of metabolites and examine their association with total
and subtypes of coffee consumption.
Other studies examining the ability of metabolites to discriminate between coffee consumption
categories suggested that trigonelline could be a useful marker of coffee consumption [13]. Regarding
caffeine, few studies have assessed its discriminating accuracy with inconsistent results [14,15]. Caffeine
is also found in tea, soft drinks, and other food items [16] making it difficult to control for this.
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Using a validated multiplatform metabolomics analysis, cross-sectional associations between
plasma levels of identified metabolites with self-reported total, caffeinated, or decaffeinated coffee
consumption were examined in participants of the PREDIMED (Prevención con DietaMediterránea)
study. The ability of metabolites to discriminate between total and the aforementioned types of coffee
consumption categories was also investigated.
2. Materials and Methods
2.1. Study Design
This study is a cross-sectional evaluation of baseline data from two nested case-cohort studies [17]
within the PREDIMED trial (ISRCTN35739639), a primary prevention cardiovascular disease (CVD) trial
conducted in 7447 participants free of cardiovascular events at baseline but at high cardiovascular risk.
Participants were men (55–80 years) and women (60–80 years) without CVD at baseline and fulfilling at
least one of the two following criteria; presence of T2D or three or more major cardiovascular risk factors.
A detailed description of the PREDIMED trial can be found elsewhere [18,19]. In brief, 7447 participants
were randomly assigned to a Mediterranean diet regime, supplemented with extra-virgin olive oil;
a Mediterranean diet supplemented with mixed nuts, or a control diet consisting of advice to reduce
fat intake. All participants provided written informed consent, and the study protocol and procedures
were approved according to the ethical standards of the Declaration of Helsinki. The Institutional
Review Board (IRB) of Hospital Clinic (Barcelona, Spain) approved the study protocol on July 2002.
This IRB is accredited by the US Department of Health and Human Services (DHHS). Later, the IRBs of
all other centers also approved the protocol.
2.2. Subjects Selection
For the present study, 1871 out of 1882 PREDIMED subjects with available metabolomics data
from the CVD [17] and T2D [20] projects, who completed a validated semiquantitative 137-item food
frequency questionnaire (FFQ) were included [21]. Nutrient and energy intakes were calculated using
Spanish food composition tables [22]. Participants (n = 34) who had extremes daily energy intake (<500
or >3500 kcal/day for women and <800 or >4000 kcal/day for men) were excluded from the present
analysis as well as those (n = 3) with equal or more than 20% missing values in metabolites leaving
1834 subjects for further analyses (Figure 1). Two questions from the FFQ concerned the average
consumption of coffee with and without caffeine during the previous 12 months. Validity of the FFQ for
coffee, estimated by the intraclass correlation coefficient was 0.75. When coffee was treated as categorical
variable (consumers vs. nonconsumers) the Kappa coefficient was 0.58. Ten categories were provided,
ranging from “never or almost never” to “6 times/day or more”. Furthermore, the usual portion size
was assessed, with 1 cup defined as 50 mL. For the present analyses, the total coffee consumption
was calculated as the sum of caffeinated and decaffeinated coffee. Due to the characteristics of the
population being at high risk of CVD and >86% of them reported to have hypertension, the majority
of them (n = 363) presented daily coffee consumption of 50 mL per day followed by 241 participants
consuming 125 mL per day. Subsequently, coffee consumers were selected with at least 50 mL per day
coffee consumption. We also separated caffeinated and decaffeinated coffee consumers and excluded
overlapping cases in order to avoid their confounding effect on associations between metabolites and
types of coffee consumption. There were 512 caffeinated coffee consumers and 721 decaffeinated coffee
consumers. We categorized participants into (1) two groups of total coffee, 285 nonconsumers (0 mL
coffee per day) vs. 1379 consumers (50 mL or more coffee per day); (2) two groups of caffeinated coffee,
285 nonconsumers (0 mL coffee per day) vs. 512 consumers (50 mL or more coffee per day); and (3)
two groups of decaffeinated coffee, 285 nonconsumers (0 mL coffee per day) vs. 721 consumers (50 mL
or more coffee per day). Finally, the consumption of other sources of caffeine, including tea and cocoa
was relatively low (n = 284 and n = 115, respectively) among the 1664 study participants.
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Figure 1. Flowchart of study participants. *, Extremes of energy are defined as out of the range
800–4000 Kcal/day in males and 500–3500 Kcal/day in females. Abbreviations: CVD, cardiovascular
disease; FFQ, food frequency questionnaire; T2D, type 2 diabetes.
2.3. Metabolomics
Fasting (for ≥8 h) plasma EDTA samples were collecte from subjects and stored at −80 ◦C. Pairs of
samples for each participant were randomly ordered and analyzed using two liquid chromatography
tandem mass spectrometry (LC–MS) methods to measure polar metabolites and lipids as described
previously [23–25]. Briefly, amino acids and other polar metabolites were profiled with a Shimadzu
Nexera X2 U-HPLC ( himadzu Corp.) coupled to a Q Ex ctive mass spectrometer (ThermoFisher
Scientific). Metabolites were extracted from plasma (10 µL) using 90 µL of 74.9:24.9:0.2 (v/v/v) of
acetonitrile/methanol/formic acid containing stable isotope-labeled internal standards (valine-d8
(Sigma-Aldrich) and phenylalanine-d8 (Cambridge Isotope Laboratories)). The samples were
centrifuged (10 min; 9000× g; 4 ◦C) and the super atants w re i jected directly o to a 150 × 2-mm,
3-µm Atlantis HILIC column (Waters). The column was eluted isocratically at a flow rate of 250 µL/min
with 5% mobile phase A (10 mmol ammonium formate/L and 0.1% formic acid in water) for 0.5 min
followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 min.
MS analyses were carried out using electrospray ionization in the positive-ion and full-scan spectra
were acquired over 70–800 m/z. Lipi s were profiled using a Shimadzu Nexer X2 U-HPLC (Shimadzu
Corp.; Marlborough, MA) coupled to an Exactive Plus orbitrap mass spectrometer (Thermo Fisher
Scientific; Waltham, MA). Lipids were extracted from plasma (10 µL) using 190 µL of isopropanol
containing 1,2-didodecanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids; Alabaster, AL) as
an internal standard. Lipid extracts (2 µL) were injected onto a 100 × 2.1 mm, 1.7 µm ACQUITY
BEH C8 column (Waters; Milford, MA). The column was eluted isocratically with 80% mobile phase
A (95:5:0.1 v/v/v 10 mM ammonium acetate/methanol/formic acid) for 1 min followed by a linear
gradient to 80% mobile-phase B (99.9:0.1 v/v methanol/formic acid) over 2 min, a linear gradient to
100% mobile phase B over 7 min, then 3 min at 100% mobile-phase B. MS analyses were carried out
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using electrospray ionization in the positive ion mode using full scan analysis over 200 to 1100 m/z.
Raw data were processed using Trace Finder version 3.1 and 3.3 (Thermo Fisher Scientific) and
Progenesis QI (Nonlinear Dynamics; Newcastle upon Tyne, UK). Polar metabolite identities were
confirmed using authentic reference standards and lipids were identified by head group and total
acyl carbon number and total acyl double bond content. To enable assessment of data quality and to
facilitate data standardization across the analytical queue and sample batches, pairs of pooled plasma
reference samples were analyzed at intervals of 20 study samples. One sample from each pair of pooled
references served as a passive QC sample to evaluate the analytical reproducibility for measurement of
each metabolite while the other pooled sample was used to standardize at using a “nearest neighbor”
approach. Standardized values were calculated using the ratio of the value in each sample over the
nearest pooled plasma reference multiplied by the median value measured across the pooled references.
Plasma levels of 398 metabolites were measured.
2.4. Statistical Analysis
Baseline characteristics of study participants were described according to nonconsumers and
frequent total coffee consumers as means (SD) for quantitative traits and percentages for categorical
variables. From the 398 metabolites measured in the present study, 11 metabolites were removed due
to high number of missing values (i.e., ≥20%), leaving 387 metabolites for further analysis. Missing
values of individual metabolites were imputed (in those metabolites with less than 20% of missing
values) using the random forest imputation approach (“missForest” R package). Missing values are
those determinations that were below the limit of detection. The levels of metabolites were normalized
and scaled to multiples of 1 SD with the rank-based inverse normal transformation. Due to the
high dimensionality and collinear nature of the data, logistic regression with elastic net penalty was
implemented in the “glmnet” R package (alpha = 0.5) to build a discrimination model for frequent
coffee consumption. We performed 10-fold cross-validation to find the optimal value of the tuning
parameter that result in a mean squared error within 1-SD of the minimum [26]. The discrimination
accuracy was examined based on parameters of lamda.min. The discrimination model scores were
computed as the weighted sum of all metabolites with weights equal to the regression coefficients
from the discrimination models. To estimate the discrimination accuracy we split the data into 90% set
and 10% set. Within the 90% set, we used the same elastic net procedure we used to build the model.
Another 10-fold cross-validation was used to tune the model parameters. Then, we used the outer 10%
set to evaluate the model built at the previous step. This procedure guarantees that the outer 10% set is
completely separated from the model building procedure, thus the discriminative accuracy estimated
in this step is unbiased. We then repeated all these steps for 10 times and averaged their discriminative
accuracy in the 10% set. Since each of them is unbiased estimate of discriminative accuracy, the average
is also unbiased. Logistic regression analysis was also performed and the derived coefficients were used
to build models consisting of either only caffeine or 5-acetylamino-6-amino-3-methyluracil as concerns
total and caffeinated coffee. The area under curve (AUC) was used to assess the discriminating power of
the discrimination models for total and subtypes of coffee consumption. We compared the AUCs of the
models including metabolites selected from elastic net regression analysis with a model including only
caffeine or 5-acetylamino-6-amino-3-methyluracil using a nonparametric method. All analyses were
performed using R statistical package 3.4.3 (www.r-project.org) (R Development Core Team, 2012).
3. Results
3.1. Participants’ Characteristics
Participants’ characteristics are summarized in Table 1. The mean age of participants at baseline
was 67.1 years and the mean BMI was 29.9 kg/m2. As compared with nonconsumers, those participants
consuming coffee were more likely to be men, current smokers, and to have a higher prevalence of
hypercholesterolemia in addition to higher BMI (Table 1).
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Table 1. Characteristics of the study subjects according to coffee and types of consumption.
Non-Coffee Consumers Total Coffee Consumers Caffeinated CoffeeConsumers
Decaffeinated
Coffee Consumers Total Subjects
Characteristic n = 285 n = 1379 n = 512 n = 721 n = 1664
Coffee consumption (mL/day) * 0 (0, 0) 50 (50, 475) 50 (50, 250) 50 (50, 350) 50 (0, 475)
Male sex, N (%) 102 (35.8) 591 (42.9) b 257 (50.2) b 265 (36.8) 693 (41.6)
Age (years) 67.64 ± 6.25 67.04 ± 5.94 66.32 ± 5.93 a 67.71 ± 5.94 67.14 ± 6
Body mass index (kg/m2) 29.42 ± 3.42 30.03 ± 3.62 a 29.7 ± 3.52 30.25 ± 3.7 a 29.92 ± 3.59
Waist circumference (cm) 99.61 ± 9.9 100.29 ± 10.22 100.33 ± 9.67 100.26 ± 10.56 100.17 ± 10.17
Smoking, N (%)
Never 196 (68.8) 793 (57.5) b 262 (51.2) b 461 (63.9) 989 (59.4)
Former 58 (20.4) 344 (24.9) 131 (25.6) 173 (24.0) 402 (24.2)
Current 31 (10.9) 242 (17.5) 119 (23.2) 87 (12.1) 273 (16.4)
Type 2 diabetes, N (%) 80 (28.1) 375 (27.2) 150 (29.3) 189 (26.2) 455 (27.3)
Dyslipidemia, N (%) 202 (70.9) 1077 (78.1) b 411 (80.3) b 553 (76.7) 1279 (76.9)
Hypertension, N (%) 254 (89.1) 1192 (86.4) 426 (83.2) b 640 (88.8) 1446 (86.9)
Family history of CVD, N (%) 79 (27.7) 338 (24.5) 123 (24.0) 188 (26.1) 417 (25.1)
Cardiac medication, N (%) 25 (9) 122 (9.1) 42 (8.4) 72 (10.3) 147 (9.1)
Antihypertensive agents, N (%) 211 (74.6) 1034 (75.1) 360 (70.5) 566 (78.7) 1245 (75)
Lipid-lowering medication, N (%) 120 (42.3) 653 (47.5) 225 (44) 358 (49.8) 773 (46.6)
Insulin medication, N (%) 8 (2.8) 57 (4.1) 16 (3.1) 32 (4.5) 65 (3.9)
Oral antidiabetics, N (%) 51 (18) 262 (19) 112 (21.9) 122 (17) 313 (18.9)
MedDiet score 8.73 ± 1.86 8.63 ± 1.86 8.54 ± 1.93 8.74 ± 1.83 8.65 ± 1.86
Data shows mean ± SD or number (%).* median (min, max). a p-value < 0.05 (Student’s t-test between coffee categories). b p-value < 0.05 (X2 between coffee categories).
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3.2. Associations between Plasma Metabolites and Total Coffee Consumption
Tables 2 and 3 show selected metabolites (n = 11) ranked from the highest to the
lowest elastic net positive and negative regression coefficients for total coffee consumption.
Five-acetylamino-6-amino-3-methyluracil (AAMU), caffeine, cotinine, and sphingomyelin 24:0 were
positively associated, while proline betaine, kynurenic acid, glycocholate, lactate, glyco-deoxy-chenodeox,
sucrose, and 7-methylguanine were negatively associated with total coffee consumption.
Metabolites (n = 10) ranked from the highest to the lowest elastic net positive and negative
regression coefficients for caffeinated coffee consumption are displayed in Tables 2 and 3,
respectively. Positive regression coefficients were found for four metabolites, caffeine, AAMU,
sphingomyelin 24:0 and cotinine; while negative for sucrose, proline betaine, acetaminophen,
one lyso-phosphatidylethanolamine (LPE) (16:0), piperine, and hypoxanthine.
Regarding decaffeinated coffee consumption, positive regression coefficients were found for
five metabolites, including hydroxyhippurate, alpha-glycerophosphate, one sphingomyelin (24:0),
hippurate, and phosphatidylcholine 40:6, while negative for LPE 16:0, phosphocreatine, and allantoin.
Table 2. Metabolites ranked from the highest to the lowest elastic net positive regression coefficients
for coffee and its types consumption.
Total Coffee Caffeinated Coffee Decaffeinated Coffee
AAMU
0.462
Caffeine
0.545
Hydroxyhippurate
0.065
Caffeine
0.330
AAMU
0.140
Alpha-glycerophosphate
0.047
Cotinine
0.022
C24:0 SM
0.031
C24:0 SM
0.018
C24:0 SM
0.015
Cotinine
0.015
Hippurate
0.014
C40:6 PC
0.006
Metabolites selected at least once after running the elastic net model 10 times using the parameter “lamda.min”
inthe case of total and decaffeinated coffee or “lambda.1se” in the case of caffeinated coffee after the “cv.glmnet”
function procedure. Abbreviations: AAMU, 5-Acetylamino-6-amino-3-methyluracil; SM, sphingomyelin; PC,
phosphatidylcholine. Total coffee: consumers ≥50 mL/day (n = 1379) vs. nonconsumers (n = 285); caffeinated coffee:
consumers ≥50 mL/day (n = 512) vs. nonconsumers (n = 285); decaffeinated coffee: consumers ≥50 mL/day (n = 721)
vs. nonconsumers (n = 285).
Table 3. Metabolites ranked from the highest to the lowest elastic net negative regression coefficients
for coffee and its types consumption.
Total Coffee Caffeinated Coffee Decaffeinated Coffee
Proline betaine
−0.031
Sucrose
−0.062
C16:0 LPE
−0.025
Kynurenic acid
−0.018
Proline betaine
−0.019
Phosphocreatine
−0.017
Glycocholate
−0.016
Acetaminophen
−0.017
Allantoin
−0.009
Lactate
−0.016
C16:0 LPE
−0.011
Glyco-deoxy-chenodeox
−0.013
Piperine
−0.006
Sucrose
−0.007
Hypoxanthine
−0.002
7-methylguanine
−0.006
Metabolites selected at least once after running the elastic net model 10 times using the parameter “lamda.min”
in the case of total and decaffeinated coffee or “lambda.1se” in the case of caffeinated coffee after the “cv.glmnet”
function procedure. Abbreviations: LPE, lyso-phosphatidylethanolamine. Total coffee: consumers ≥50 mL/day
(n = 1379) vs. nonconsumers (n = 285); caffeinated coffee: consumers ≥50 mL/day (n = 512) vs. nonconsumers
(n = 285); decaffeinated coffee: consumers ≥50 mL/day (n = 721) vs. nonconsumers (n = 285).
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3.3. Discrimination of Total and Types of Coffee Consumption
To explore the discriminative ability of the multimetabolite models, AUC analyses were carried out.
The AUCs were 0.60 (95% CI 0.56–0.64) (Figure 2A), 0.78 (95% CI 0.75–0.81) (Figure 2B), and 0.52 (95%
CI 0.49–0.55) in the multimetabolite models for total, caffeinated, and decaffeinated coffee consumption,
respectively. The AUC was significantly higher for total coffee (AUC: 0.66 (95% CI 0.62–0.71)) when
only caffeine was kept in the model, p = 0.014. Significantly higher AUC was also found as compared
to multimetabolite score for caffeinated coffee consumption (AUC: 0.79 (95% CI 0.77–0.82)), p = 0.029.
On the other hand, AAMU had significantly lower AUCs for total (0.56 (95% CI 0.53–0.60)) and
caffeinated (0.66 (95% CI 0.60–0.73)) coffee.
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4. Discussion
In the present study, specific metabolites associated with total, caffeinated and decaffeinated coffee
consumption were identified among participa ts of the PREDIMED study. It was also demonstrated
that caffeine alone had better discriminative ab lity for otal and caffeinated coffee consumption
as compared to a set f metab lites which also included caffeine, and th refore may be used as
biomarker of consumption complementing traditional dietary assessment tools. Similarly, a previous
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cross-sectional study found that urine caffeine is useful (AUC: 0.85) to distinguish between those
subjects drinking less than one caffeinated coffee per week versus at least one caffeinated coffee [14].
However, in the aforementioned study risk of overfitting is high due to the lack of internal or external
validation [15].On the other hand, a previous metabolomics study showed that caffeine was much
less performant to predict coffee consumption in a cohort study than other coffee metabolites alone
or in combination [27]. We found a low discrimination of decaffeinated coffee categories from the
multimetabolite model. Recently, a cross-sectional study investigating how accurately could plasma
trigonelline discriminate consumers from nonconsumers of coffee suggested that this plant alkaloid
may serve as a useful marker of coffee consumption (AUC:0.92) [13]. However, the lack of internal or
external validation limits the generalizability of this marker.
A consistent set of three metabolites was positively associated with total and caffeinated coffee
consumption. Plasma caffeine and one of its major metabolites, AAMU, reflect caffeine exposure [28].
Cotinine, the main metabolite of nicotine [29] could confirm the higher prevalence of tobacco exposure
in frequent coffee consumers in our study. Higher cigarette consumption has been suggested to causally
increase coffee consumption [30].
One sphingomyelin (SM 24:0) was also positively associated with total, caffeinated and
decaffeinated coffee consumption. A previous study among German elders found two classes
of SMs, one containing a hydroxygroup and the other having an additional carboxygroup to be
directly associated with coffee consumption [6]. Furthermore, we found one phosphatidylcholine
(C40:6) positively associated with decaffeinated coffee consumption. A cross-sectional analysis in
participants in the EPIC-Potsdam study suggests associations of coffee consumption with certain
acyl-alkyl-phosphatidylcholines, including C40:6 [7].
The positive association found in the present study between alpha-glycerophosphate (alpha-GP)
and decaffeinated coffee is interesting since this metabolite is formed from glycolysis and previous
experiments using perfused rat adipocytes propose a model, where alpha-GP combines with long-chain
coenzyme A (LC-CoA) to form triacylglycerol (TAG), thus decreasing LC-CoA and its inhibition
of TAG lipases leading to release of free fatty acids and glycerol [31]. Finally, hippurate, a gut
microbial metabolite of polyphenol metabolism, has been previously associated with the consumption
of polyphenol-rich foods including coffee [32].
Concerning metabolites negatively associated with total coffee consumption, proline betaine had
the highest coefficient in our study. This metabolite is a biomarker for citrus fruit consumption [33].
Caffeine has been considered as a diuretic, mainly because of its caffeine content [34], and this action
could increase the renal excretion of proline betaine as well as ofpiperine, the major bioactive component
of pepper [35], acetaminophen also known as paracetamol and 7-methylguanine. The latter metabolite
is considered to be a useful marker of DNA damage caused by nitrosamines in tobacco smoke and has
been found significantly higher in the urine of smokers than in non-smokers [36]. Sucrose was also
recorded to be negatively associated with total and caffeinated coffee consumption and its levels in
blood may reflect gastric permeability to sucrose [37].
Inverse associations between coffee consumption and systemic levels of a number of different
inflammatory markers including interferon-γ (IFN-γ) have been reported [38] and IFN-γ-mediated
breakdown of tryptophan to kynurerine and downstream kynurenine metabolites like kynurenic acid
could be counteracted by the consumption of coffee [39]. This could partially explain the inverse
association between kynurenic acid and coffee consumption in our study.
Plasma glycocholate levels were also recorded to be negatively associated with total coffee drinking
in our study. Glycocholic acid is a conjugated bile acid (cholic acid with glycine) synthesized in the
liver and is involved in dietary lipids emulsification and cholesterol absorption [40]. Whether coffee
consumption has an effect on glycocholic acid synthesis and/or release into circulation is unknown and
needs further investigation. A disruption in bile acid synthesis could lead to cholesterol homeostasis
dysregulation [41]. Meta-analyses of clinical trials of the effect of coffee consumption on blood lipids
suggest increases in cholesterol levels [42,43], which is in line with our findings.
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The inverse association between coffee consumption and plasma lactate levels merits discussion.
Caffeine is known to have a stimulating effect on the central nervous system. An increase in energy
expenditure was observed in a small study of older men after moderate coffee consumption [44].
Furthermore, a study conducted by Engels and Haymes (1992) [45] showed increases in pre-exercise
free fatty acids, glycerol, and lactate concentrations in sedentary men after a single dose of caffeine
(5 mg·kg−1). However, if free fatty acids are the main source of fuel, lactate levels should not increase.
Finally, the physiological significance of the inverse association of LPE 16:0 with caffeinated and
decaffeinated coffee consumption requires further work hypotheses and research to be determined.
Allantoin is produced from the nonenzymatic oxidation of uric acid in humans and is considered
to be a specific biomarker of oxidative stress [46]. It has been hypothesized that the diuretic action of
caffeine might lower blood uric acid concentrations [47] and subsequent allantoin production. However,
in our study lower plasma levels of allantoin were associated with decaffeinated coffee drinking.
The results of the present study should be interpreted in the context of its limitations and strengths.
First, although the FFQ used to assess coffee consumption was validated, misclassification bias cannot
be completely excluded. Secondly, even though we used a comprehensive metabolic analysis to cover
a wide range of metabolites, some of those previously associated with coffee consumption were neither
selected by the model nor identified in the platforms we used. Thirdly, the cross-sectional design does
not allow making any causal inference of the observed associations, and therefore both directions are
plausible. Finally, participants were elderly Mediterranean individuals at high cardiovascular risk
consuming low amounts of coffee per day and this may limit the generalizability of the findings to
other age-groups or populations. Regarding strengths, we have used a multimetabolomics approach
in order to analyze a wide range of biochemical compounds in a relatively high sample size and have
internally cross-validated our results.
In conclusion, different sets of plasma metabolites were associated with the consumption of
50 mL or more per day of total, caffeinated and decaffeinated coffee in a Mediterranean population
at high cardiovascular risk. These sets consisted of caffeine; 5-acetylamino-6-amino-3-methyluracil;
cotinine; lipid species, such as sphingomyelin, phosphatidylethanolamine, and phosphatidylcholine;
and other metabolites including alpha-glycerophosphate, hippurate, kynurenic acid, glycocholate,
lactate, and allantoin. Plasma caffeine appeared to best discriminate total and caffeinated coffee
consumers versus nonconsumers. Despite a low discriminative ability of decaffeinated coffee observed
from the multimetabolite model this suggests that other potential metabolites could be used as
candidate biomarkers of consumption. Therefore, our comprehensive metabolic analysis did not result
in new, reliable potential set of metabolites for coffee consumption.At least in our population the
selected metabolites did not accurately discriminate coffee consumers. Dietary questionnaires remain
practical and one of the most affordable way to gather coffee intake data. Further studies are needed
for assessing the involvement of the identified metabolites in health or disease.
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